Another implanted patient in InVivo Therapeutics' INSPIRE study improved from a complete AIS A spinal cord injury to an incomplete AIS B spinal cord injury, according to pharmiweb.com.
Here are five things to know:
1. This patient marks the fourth patient to demonstrate AIS grade improvement with at least two months of follow-up data.
2. To meet the Objective Performance Criterion, InVivo needs to observe one more improved patient case.
3. The company plans to enroll 13 more patients to reach 20 patients at six months.
4. InVivo hopes to reach full enrollment by the end of 2016 and file for Humanitarian Device Exemption approval in 2017.
5. The INSPIRE study tests the Neuro-Spinal Scaffold for safety and neurologic recovery in patients with complete thoracic AIS A spinal cord injury.